- Home
- RFM vs THAR Comparison
RFM vs THAR Comparison
Compare RFM & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFM | THAR |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.4M | 90.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RFM | THAR |
|---|---|---|
| Price | $14.06 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.7K | ★ 531.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.89 | $0.95 |
| 52 Week High | $16.41 | $9.08 |
Technical Indicators
Market Signals| Indicator | RFM | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 59.09 |
| Support Level | $13.86 | $2.20 |
| Resistance Level | $14.09 | $3.56 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 61.29 | 63.60 |
Price Performance
Historical ComparisonAbout RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.